We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Or first pitch for Orph on Nasdaq?
Or Nasdaq for Orph?
Open Orphan's Executive Chairman Cathal Friel is joining a panel of #digitalhealth leaders to discuss the future of healthcare and technology at American Digital Week
@DitechMedia
on 21st October https://dw.digital4america.com
DIM?
What additional baggage Elrico? What I was asking is if CF was approached with a decent offer for the core business solely and left with dim, imutex and prep to spin off at a later date is that not feasible?
I’ve always been a fan of Mr B’s pithy investing quotes, and here’s one of my favourites:
‘No matter how great the talent or efforts, some things just take time. You can't produce a baby in one month by getting nine women pregnant.’
Feels particularly pertinent when considering the Orph investment case right now. Patience and time needed. But the long game looks great IMO.
Northseatiger1,
Why would you throw away 30-60p in dividends away? Leaving aside your crazy POV, any suiter will not want additional baggage. They will want a narrow-focused company uncluttered with subsidiaries that will prove to be a distraction. What would you expect ORPH to be worth now? It will not command £300m now, so why not allow the company to build revenues through its business model. What's a year or two in the grand scheme?
Sorry, but you appear not to understand the business strategy, or understand the value currently locked inside the company. If POLB was worth £50 million at IPO, what do you think DIM is worth? IMHO at least 1.5/2 x this.
I'm definitely going to hold him to this timeline. I'm wondering how he cant just sell Orph now without the spin offs? Just write it into the deal?
Unrelated…but the UK Spac (talked about previously on here) should be trading again in the next few weeks hopefully. Will be interesting to see what price it opens at following the reverse takeover of Hellenic (the medical cannabis company) if it is given the green light to trading in UK by regulators. I think possibly CF’s Raglan Capital has some interest with it? Adyor
Yes, 60p SP by Xmas won’t disappoint me….:-)
Yes, I noticed that. And talking about all the deals that (he thinks) POLB is about to do. He just can't help himself, can he? Note that JS then thanked him for his "colourful" introduction. It can't be easy as CEO having a chairman like that.
CF opening the Poolbeg Pharma session and mentioned that there will be news on ORPH between now and Xmas for our long suffering shareholders and you won't be disappointed.
GLA